Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer

Journal of Gastrointestinal Surgery

Volumn 14, Issue 7, 2010, Pages 1151-1158

  Izuishi, Kunihiko ^a   Yamamoto, Yuka ^a   Sano, Takanori ^a   Takebayashi, Ryusuke ^a   Masaki, Tsutomu ^b   Suzuki, Yasuyuki ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

18 Fluorodeoxyglucose; Multidetector row computed tomography; Pancreatic cancer; Positron emission tomography

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; BONE TUMOR; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LIVER TUMOR; LYMPH NODE METASTASIS; MALE; METASTASIS; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; BONE NEOPLASMS; DIAGNOSTIC USE; LIVER NEOPLASMS; LYMPHATIC METASTASIS; PANCREATIC NEOPLASMS; SECONDARY;

AGED; BONE NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78649688880     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-010-1207-x     Document Type: Article

References (24)

1. Brennan DD, Zamboni GA, Raptopoulos VD et al. Comprehensive preoperative assessment of pancreatic adenocarcinoma with 64-section volumetric CT. Radiographics 2007; 27: 1653-1666.
2. Huguet F, Girard N, Guerche CS, et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009; 27: 2269-2277.
3. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277.
4. Vin Y, Sima CS, Getrajdman GI, et al. Management and outcomes of postpancreatectomy fistula, leak, and abscess: results of 908 patients resected at a single institution between 2000 and 2005. J Am Coll Surg 2008; 207: 490-498.
5. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009; 361: 32-39.
6. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007; 110: 3507-3516.
7. Zafra M, Ayala F, Gonzalez-Billalabeitia E, et al. Impact of whole-body 18F-FDG PET on diagnostic and therapeutic management of Medical Oncology patients. Eur J Cancer 2008; 4: 1678-1683.
8. Annovazzi A, Peeters M, Maenhout A, et al. 18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract. Gastroenterology 2003; 125: 1235-1245.
9. Heinrich S, Goerres GW, Schäfer M et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005; 242: 235-243.
10. Delbeke D, Rose DM, Chapman WC, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999; 40: 1784-1791.
11. Saif MW, Cornfeld D, Modarresifar H, et al. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients. J Gastrointestin Liver Dis 2008; 17: 173-178.
12. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41: 1369-1379.
13. Higashi T, Saga T, Nakamoto Y, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)-usefulness and limitations in clinical reality. Ann Nucl Med 2003; 17: 261-279.
14. Fortner JG, Klimstra DS, Senie RT, et al. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 1996; 223: 147-153.
15. Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005; 104: 1066-1074.
16. Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001; 285: 914-924.
17. Frohlich A, Diederichs CG, Staib L. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 1999; 40: 250-255.
18. Terauchi T, Murano T, Daisaki H, et al. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography: a preliminary report. Ann Nucl Med 2008; 22: 379-385.
19. Yamamoto F, Nakada K, Zhao S, et al. Gastrointestinal uptake of FDG after N-butylscopolamine or omeprazole treatment in the rat. Ann Nucl Med 2004: 18: 637-640.
20. Gambhir SS, Shepherd JE, Shah BD, et al. Analytical decision model for the cost-effectiveness management of solitary pulmonary nodules. J Clin Oncol 1998; 16: 2113-2125.
21. Ngeow JY, Quek RH, Ng DC, et al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol 2009; 20: 1543-1547.
22. Miele E, Spinelli GP, Tomao F, et al. Positron emission tomography (PET) radiotracers in oncology-utility of 18F-fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). J Exp Clin Cancer Res 2008; 27: 52.
23. Bang S, Chung HW, Park SW, et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol. 2006; 40: 923-929.
24. Parsons CM, Sutcliffe JL, Bold RJ. Preoperative evaluation of pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 2008; 15: 429-435.